{"name":"Glenmark Pharmaceuticals","slug":"glenmark","ticker":"GLENMARK.NS","exchange":"NSE","domain":"glenmarkpharma.com","description":"Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai.","hq":"Mumbai, India","founded":1995,"employees":"15800","ceo":"Glenn Saldanha","sector":"Dermatology / Respiratory Generics","stockPrice":2340.6,"stockChange":63,"stockChangePercent":2.77,"marketCap":"$6.9B","metrics":{"revenue":1724195309.0312192,"revenueGrowth":15.1,"grossMargin":70.7,"rdSpend":0,"netIncome":111232757.746176,"cash":280956533.3712896,"dividendYield":0.22,"peRatio":61.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Salmeterol patent cliff ($1.4B at risk)","drug":"Salmeterol","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Fluticasone patent cliff ($2.1B at risk)","drug":"Fluticasone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"GRC 17356","genericName":"GRC 17356","slug":"grc-17356","indication":"Other","status":"phase_2"},{"name":"DYMISTA nasal spray","genericName":"DYMISTA nasal spray","slug":"dymista-nasal-spray","indication":"Allergic rhinitis (seasonal and perennial)","status":"phase_3"},{"name":"GRC 8200","genericName":"GRC 8200","slug":"grc-8200","indication":"Other","status":"phase_2"},{"name":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","slug":"placebo-of-tacrolimus-ointment","indication":"Prevention of organ rejection in transplant patients","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Diclofenac Sodium gel, 1%","genericName":"Diclofenac Sodium gel, 1%","slug":"diclofenac-sodium-gel-1","indication":"Topical treatment of localized pain and inflammation in musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, sprains, strains)","status":"marketed"},{"name":"Voltaren® Gel","genericName":"Voltaren® Gel","slug":"voltaren-gel","indication":"Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","status":"marketed"},{"name":"Protopic® ointment, 0.1%","genericName":"Protopic® ointment, 0.1%","slug":"protopic-ointment-0-1","indication":"Atopic dermatitis","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Elidel® (pimecrolimus) Cream","genericName":"Elidel® (pimecrolimus) Cream","slug":"elidel-pimecrolimus-cream","indication":"Atopic dermatitis (eczema) in patients ≥2 years of age","status":"phase_3"},{"name":"Placebo of Pimecrolimus Cream, 1%","genericName":"Placebo of Pimecrolimus Cream, 1%","slug":"placebo-of-pimecrolimus-cream-1","indication":"Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions","status":"phase_3"}]}],"pipeline":[{"name":"Diclofenac Sodium gel, 1%","genericName":"Diclofenac Sodium gel, 1%","slug":"diclofenac-sodium-gel-1","phase":"marketed","mechanism":"Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.","indications":["Topical treatment of localized pain and inflammation in musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, sprains, strains)","Post-traumatic inflammation and pain relief"],"catalyst":""},{"name":"GRC 17356","genericName":"GRC 17356","slug":"grc-17356","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Voltaren® Gel","genericName":"Voltaren® Gel","slug":"voltaren-gel","phase":"marketed","mechanism":"Voltaren Gel is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce local inflammation and pain at the site of application.","indications":["Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","Acute pain relief from minor sprains, strains, and contusions"],"catalyst":""},{"name":"DYMISTA nasal spray","genericName":"DYMISTA nasal spray","slug":"dymista-nasal-spray","phase":"phase_3","mechanism":"DYMISTA is a nasal spray combining azelastine (a selective H1-receptor antagonist) and fluticasone propionate (a corticosteroid) to reduce allergic rhinitis symptoms through dual anti-inflammatory and antihistamine action.","indications":["Allergic rhinitis (seasonal and perennial)"],"catalyst":""},{"name":"Elidel® (pimecrolimus) Cream","genericName":"Elidel® (pimecrolimus) Cream","slug":"elidel-pimecrolimus-cream","phase":"phase_3","mechanism":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.","indications":["Atopic dermatitis (eczema) in patients ≥2 years of age","Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis"],"catalyst":""},{"name":"GRC 8200","genericName":"GRC 8200","slug":"grc-8200","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of Pimecrolimus Cream, 1%","genericName":"Placebo of Pimecrolimus Cream, 1%","slug":"placebo-of-pimecrolimus-cream-1","phase":"phase_3","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":["Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions"],"catalyst":""},{"name":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","slug":"placebo-of-tacrolimus-ointment","phase":"phase_3","mechanism":"Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation.","indications":["Prevention of organ rejection in transplant patients"],"catalyst":""},{"name":"Protopic® ointment, 0.1%","genericName":"Protopic® ointment, 0.1%","slug":"protopic-ointment-0-1","phase":"phase_3","mechanism":"Protopic ointment, 0.1% works by inhibiting the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to reduce inflammation.","indications":["Atopic dermatitis","Severe psoriasis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Glenmark Pharmaceuticals reports Q3 FY2024 results","summary":"Glenmark Pharmaceuticals reported its Q3 FY2024 results, with revenue of ₹2,444 crore and a net loss of ₹1,144 crore.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Glenmark Pharmaceuticals partners with US-based company for respiratory therapy","summary":"Glenmark Pharmaceuticals has partnered with a US-based company to develop a new respiratory therapy.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"regulatory","headline":"Glenmark Pharmaceuticals receives FDA approval for new generic product","summary":"Glenmark Pharmaceuticals has received FDA approval for a new generic product, expanding its portfolio of dermatology and respiratory generics.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxObUQtVlRTYVhzTURxZHlKdWszZUZxN0g3a2d2dFpWZVYxZnFhZHFKQ1BOZlQ4Nmp1YmlwRW1xTU54ZkJFSDYzN0I5Ynp1eGEtQ1UzOU5ETFRvS2lWZjY5QVpueEttRDVoQy04U3BMd2hic0kwaHhJY0xwbFdyLUVpRURVM3VPR3BYVnUtRkJIWXJjbDFfS1pWTkVSUG9uUVRS?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo Finance UK","summary":"Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio - Yahoo Finance UK","headline":"Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcVhnbHNZTjRfREVLYTBhWU1RRjB2TTh0Y1VaR0pxNk5tcld5SGVvLUlNWDMxTkJSblhHNU9mRkVpZmEtY2FONThBNzZJV0NKNkhlSElKZFFXald4XzY2dUgyYTlQeTJwSWFzVW5LaHhVdTdndmtuZzN3Nk51eU1CeVBJd2pQWERfNElxck14OWxqbXUwaWg3TW5RNjVZNXc2Nmt1ZzRTYmlDSElyajVEUUFGSE9Md3NpY1lBandPRGdiLVRsczBaZkJjYUJoel9IT3pKbXBpWW5NSmcwZGc?oc=5","date":"2026-03-23","type":"pipeline","source":"Reuters","summary":"Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy - Reuters","headline":"Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdmZtYlNHQ2dfN19MUjZpZlFrNzBJTXVNNEpiS0FmV3N5ZVBrczNmMmZuSHNIZk5ZSTJaeU9McThtU0JIaEptY0lGOFJ5S2dlckJuVlFINHhwRlhWMXNsX2ltU2JEd201T09EYWhfRFhFa0ozUTg3aEJaa0s2QWlTTVc1U3ZGdGNFZTFfaVc0ODNDaXRpOTNGT2RRUDdyaWw4NDRTQUZOOE96cUxHT0pJY195VVFub29pemI1b2NKTlh3YkdmVGJNMjhWcFRwOTBXQTRpQlBkTzZPNHV5eHhLQg?oc=5","date":"2025-11-14","type":"regulatory","source":"Reuters","summary":"India's Glenmark posts higher quarterly profit on strong demand in N.America, Europe - Reuters","headline":"India's Glenmark posts higher quarterly profit on strong demand in N.America, Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOOXRzZ1prUXFUUnNacm1nUEg4eFBwcUlHU0k3NXRkQm1lZG9vY1U1LXdBVzhWelp3YWZpcTYzYXMwcURlS21BWElxRjEzTEFUWGRmcU9BUTlBOFA0dGUyXzVHbEg3UTV5djQ3bFJkUjdtUlFBNTRYS25uQW1ralk4cQ?oc=5","date":"2025-11-12","type":"regulatory","source":"Healthcare Radius","summary":"China approves Glenmark Pharma’s Ryaltris nasal spray for allergic rhinitis - Healthcare Radius","headline":"China approves Glenmark Pharma’s Ryaltris nasal spray for allergic rhinitis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMjk1TThWTUYxWEh6amkwZTFDcXdwOGNic2tlT3BGY0RqOHRLdENuZ0VPOHo0WjFfMXRTa2hXbjFrNXVFUUNHSzktUEdZaVlLYUdrLWhydlFaZVZPM1kxXzJDUC1iMkpTUTJWUFhLcEN1Z2pjenJQS2N4S1ZnRnM1ZUtqQkxKRDhpNmpIYVo3c0dnU1ZGQmN4bEFsS0pYalRMMVRYbE5TaEhjcFJJQWVRLWJxMXZiNUpaLWhFZWFrMlZtWW9TMWcwOVBDLWFCX0FYaFpOcGZ5WjhzY2ZDOTJRTVl3MEZORlRh?oc=5","date":"2025-11-10","type":"regulatory","source":"scanx.trade","summary":"Glenmark Pharma Secures Regulatory Approval in China for RYALTRIS®, Expanding Global Reach - scanx.trade","headline":"Glenmark Pharma Secures Regulatory Approval in China for RYALTRIS®, Expanding Global Reach","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOUDhSa0tsMk85cjZfSjFoYnpKc01EeDN3STR6UF84ei1uSEpsRE5lRnVxckNqQ0dNNC1ZOU5LWUZFX0pmOHFTLTZuMHJCdnk0VDUzVnpBZXduR0FDZVpaRl9KeWRmeHpUNzluYWtaZnlLZzNIZlFJS19CWTVNRTMySEJfV0ZFdkJnMjZqcjBQNUliVzQ3WF9lTzNqejBEVUdaMmd6SFBpeHgzbGVhN1Q0TjVvUXkwMDRYdlp4dUZyRnVHWWI5eTJmMUFYSzNGdw?oc=5","date":"2025-07-11","type":"deal","source":"Reuters","summary":"India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal - Reuters","headline":"India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNamVvTlNIMlRIOURHQnY2UEtYYmVibmRGbDlSOGxFVTAtZ2I1ckN5R0FoeTVORjBSN0Z6bkNBMXBUS2N5VWFzbXdYVnlrUHJBVnNGeU1KYTM4czhLNTZPa3RpMlZSSFlJNC1LdGVmRGxiLV9QV28tRUtzM2lKMGJ3MFJDckpEd05VaEN3?oc=5","date":"2025-07-10","type":"pipeline","source":"Yahoo Finance Singapore","summary":"India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact - Yahoo Finance Singapore","headline":"India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxObEtUR2JhbnE1clk1NlAwbDVhbG05Z050U0dKcnZsRUQ2TFBvdXBrQ1oybFhacmtfVGQwTUMyWnpsY1oxOWFMUjYzQ3BnVzdJOW00aUtwc3lDM2RYR0lxYi04T0dtUUxzWFkwZ1Qwc3hJaUNEV1VHSG1sWWhZTlJPWHQ0U1ViV212Y3BkUDdXX0lub3B5N3RRNXJuTW9BeFNSWFZpNURfd0ZWcW1yeVh0V3I1WE12WHc?oc=5","date":"2023-09-22","type":"pipeline","source":"in.investing.com","summary":"Glenmark Pharma to sell 75% stake in life sciences unit to Nirma for Rs 5,651 cr By IANS - in.investing.com","headline":"Glenmark Pharma to sell 75% stake in life sciences unit to Nirma for Rs 5,651 cr By IANS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOQW9mZFpqZjFjWnZmUk83M0NNMldaUnpucl9haUxFdXJCaWM4LXlER2t1aG9vQmt5VGkxOUoxZjkyWC1rVWNpXzIyUEVpNUtORF9uSUZIUHVZUEJFYVROTWZrdHpfVmd0Q0ptd0xlaG1ScDdYZW4wNEQtbEczR0JlU0NyeFhRSEd0dW5HNjlEa1Q3M0FucTE3dlRtTVlFeGtTdzM0TXc1TGRyY1RpX09NOTlaTlctdXRSQktuMDcyUQ?oc=5","date":"2021-07-27","type":"pipeline","source":"in.investing.com","summary":"Glenmark Life Sciences IPO: Company Aims to Raise Funds Amidst a Pharma Sell-Off - in.investing.com","headline":"Glenmark Life Sciences IPO: Company Aims to Raise Funds Amidst a Pharma Sell-Off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBOLWU3bm1SMXZvTkNFcEd1RTFRMHBaR3AzMTdWUk5JY1BIaEdJR1J4dDN5c2FFWGo0a00tWlMyR3RJWUxidF92dFd1Y0xOX2ktZmxwb2otLVZycmJBNlZDRTktRlhUVjdodGc?oc=5","date":"2018-02-03","type":"pipeline","source":"Yahoo Finance UK","summary":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) income statement - Yahoo Finance UK","headline":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) income statement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5QU2RUT1hFdlI4WHphSnpmb0NuZ2p2c0p6Mlo0OFZGWXJqQ01OMk5Yd3VSMnNPd0EwaEdoOW9UWFFQa1N0RHRtNVVjdjM4c0FWMXhIT2JydFUyMlpBeV9BdUJGLUp4dw?oc=5","date":"2017-08-08","type":"trial","source":"Yahoo Finance Australia","summary":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) stock historical prices and data - Yahoo Finance Australia","headline":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) stock historical prices and data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9mWC1hMFBqbkFZaTRfNm9mYkNvOVRDS1VTbVNjREdZcDFjcS1UQUY0dFUwc1VlWVZuSl9kQkRsOTIzWjNjejlPTTBZSlNrU1FrTlQ5X3ZOeW84TVk?oc=5","date":"2017-05-23","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Salmeterol","drugSlug":"salmeterol","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Fluticasone","drugSlug":"fluticasone","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":2100000000}],"drugCount":9,"phaseCounts":{"marketed":2,"phase_2":2,"phase_3":5},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Sun Pharmaceutical Industries","Cipla Limited","Aurobindo Pharma"],"therapeuticFocus":["Dermatology","Respiratory"],"financials":{"source":"yahoo_finance","revenue":1372890312.3485,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":1372890312.3485},{"period":"2024-03-31","value":1215153210.6560001},{"period":"2023-03-31","value":1193898732.00675},{"period":"2022-03-31","value":1271416933.45425}],"grossProfit":876055516.57525,"grossProfitHistory":[{"period":"2025-03-31","value":876055516.57525},{"period":"2024-03-31","value":705608838.616},{"period":"2023-03-31","value":714894918.8548751},{"period":"2022-03-31","value":772406853.255125}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":167439983.513,"operatingIncome":195134051.820125,"operatingIncomeHistory":[{"period":"2025-03-31","value":195134051.820125},{"period":"2024-03-31","value":65906554.278125},{"period":"2023-03-31","value":112672610.76775001},{"period":"2022-03-31","value":192166102.898}],"netIncome":109353967.85637501,"netIncomeHistory":[{"period":"2025-03-31","value":109353967.85637501},{"period":"2024-03-31","value":-156827260.7055},{"period":"2023-03-31","value":31042893.041875},{"period":"2022-03-31","value":98347941.42662501}],"eps":37.11,"epsHistory":[{"period":"2025-03-31","value":37.11},{"period":"2024-03-31","value":-53.22},{"period":"2023-03-31","value":10.53},{"period":"2022-03-31","value":33.37}],"cash":175003088.93512502,"cashHistory":[{"period":"2025-03-31","value":175003088.93512502},{"period":"2024-03-31","value":173182049.30125},{"period":"2023-03-31","value":121061800.006125},{"period":"2022-03-31","value":147308811.75725}],"totalAssets":1676141190.57275,"totalLiabilities":751985246.7215,"totalDebt":258233905.39512503,"equity":924194689.375375,"operatingCashflow":-86430194.173125,"operatingCashflowHistory":[{"period":"2025-03-31","value":-86430194.173125},{"period":"2024-03-31","value":-27721743.681500003},{"period":"2023-03-31","value":65313048.042},{"period":"2022-03-31","value":115782487.3645}],"capex":-78281519.603375,"capexHistory":[{"period":"2025-03-31","value":-78281519.603375},{"period":"2024-03-31","value":-93822443.32175},{"period":"2023-03-31","value":-63471956.816125005},{"period":"2022-03-31","value":-82516165.188875}],"freeCashflow":-164711713.77650002,"dividendsPaid":-7356636.68575,"buybacks":null,"employees":15800,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":60095352.271625005,"ebitda":76224978.19887501,"period":"2025-12-31","revenue":406044633.564625,"epsBasic":14.29,"netIncome":42109700.859875,"rdExpense":null,"epsDiluted":14.28,"grossProfit":270790170.531375,"operatingIncome":74702937.04362501},{"sga":null,"ebit":107971974.539,"ebitda":122718249.48900001,"period":"2025-09-30","revenue":627008477.8127501,"epsBasic":21.63,"netIncome":63742444.437375,"rdExpense":null,"epsDiluted":21.62,"grossProfit":494949423.94837505,"operatingIncome":231674318.56662503},{"sga":null,"ebit":16062578.4165,"ebitda":29631448.94875,"period":"2025-06-30","revenue":319502589.104875,"epsBasic":1.66,"netIncome":4894990.461625,"rdExpense":null,"epsDiluted":1.66,"grossProfit":213440528.703875,"operatingIncome":47057953.36275},{"sga":null,"ebit":7799860.417250001,"ebitda":20875691.544125002,"period":"2025-03-31","revenue":336295692.9695,"epsBasic":null,"netIncome":485624.49375,"rdExpense":null,"epsDiluted":null,"grossProfit":180379108.73400003,"operatingIncome":45838461.488875},{"sga":null,"ebit":53117815.99712501,"ebitda":65936005.05387501,"period":"2024-12-31","revenue":344835582.454,"epsBasic":12.33,"netIncome":36339541.95575,"rdExpense":null,"epsDiluted":12.33,"grossProfit":231602884.770125,"operatingIncome":49866951.64412501},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":12.55,"netIncome":null,"rdExpense":null,"epsDiluted":12.55,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2340.6,"previousClose":2277.6,"fiftyTwoWeekHigh":2474,"fiftyTwoWeekLow":1370,"fiftyTwoWeekRange":"1370.0 - 2474.0","fiftyDayAverage":2225.46,"twoHundredDayAverage":2035.22,"beta":0.31,"enterpriseValue":6744136754.220238,"forwardPE":29.2,"priceToBook":6.89,"priceToSales":4,"enterpriseToRevenue":3.91,"enterpriseToEbitda":16.02,"pegRatio":0,"ebitda":420852437.66016,"ebitdaMargin":24.4,"freeCashflow":0,"operatingCashflow":0,"totalDebt":127847389.2413696,"debtToEquity":12.8,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":11,"targetMeanPrice":2227.36,"targetHighPrice":2735,"targetLowPrice":1500,"dividendRate":5,"payoutRatio":0.13,"fiveYearAvgDividendYield":0.35,"exDividendDate":1759449600,"insiderHeldPercent":49,"institutionHeldPercent":26.9,"sharesOutstanding":282200809,"floatShares":141576013,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":37.81,"epsForward":80.06,"revenuePerShare":585.09,"bookValue":339.57,"officers":[{"age":55,"name":"Mr. Glenn Mario Saldanha","title":"Chairman, MD & CEO"},{"age":58,"name":"Ms. Cherylann Maria Pinto B.Pharm","title":"Executive Director of Corporate Services & Executive Director"},{"age":null,"name":"Mr. Harish Vinayak Kuber","title":"Company Secretary & Compliance Officer"},{"age":54,"name":"Mr. Alind  Sharma","title":"President and Chief Human Resources Officer"},{"age":58,"name":"Mr. Ulhas R. Dhuppad","title":"President & Head of Global Pharmaceutical Development"},{"age":null,"name":"Mr. Indrajit  Bose","title":"President & Chief Quality Officer"},{"age":null,"name":"Mr. Brijlal  Motwani","title":"President & Chief Quality Officer"},{"age":null,"name":"Mr. Alok  Malik","title":"President & Business Head of India Formulations"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://glenmarkpharma.com","phone":"91 22 4018 9999"}}